dc.contributor.author | Doksat, Mehmet Kerem | |
dc.date.accessioned | 2021-03-05T21:03:03Z | |
dc.date.available | 2021-03-05T21:03:03Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Doksat M. K. , "Reversible Worsening of Psychosis Due to Benzydamine in a Schizoaffective Young Girl Who is Already Under Treatment with Antipsychotics", KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.19, ss.279-284, 2009 | |
dc.identifier.issn | 1017-7833 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_d71560a2-ac31-45e0-ac19-c27eb86b18ae | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/141922 | |
dc.description.abstract | Benzydamine, available as the hydrochloride form, is an anti-inflammatory drug providing both rapid and extended pain relief in many painful inflammatory conditions, In oral dosages of 500 mg to 3000 mg it is a "deliriant" and CNS stimulant, popular in Poland and Brazil. In Brazil it is so popular that many people use it for recreational purposes. A person in a "benzydamine trip" may experience a feeling of well-being, euphoria and in higher doses hallucinations, paranoia, dry mouth and convulsions may also be experienced. In dosages of 750 mg to 2000-3000 mg benzydamine is a hallucinogen and CNS stimulant. These "triply" effects may be observed in poisoning or accidental or "on purpose" overdose cases also, hallucinosis (i.e. ego-dystonic hallucinations) is typical in such cases and generally remits spontaneously in 2 to 3 days after cessation of the drug even in children. | |
dc.language.iso | eng | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Eczacılık | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Psikiyatri | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.title | Reversible Worsening of Psychosis Due to Benzydamine in a Schizoaffective Young Girl Who is Already Under Treatment with Antipsychotics | |
dc.type | Makale | |
dc.relation.journal | KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY | |
dc.contributor.department | , , | |
dc.identifier.volume | 19 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 279 | |
dc.identifier.endpage | 284 | |
dc.contributor.firstauthorID | 193128 | |